Shares of Brainsway Ltd. Sponsored ADR (BWAY) have gained 3.5% over the past four weeks to close the last trading session at $5.33, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $11.75 indicates a potential upside of 120.5%. While the consensus price target is a much-coveted metric for investors, solely banking on this metric to make an investment decision may not be wise at a ...

BrainsWay Ltd. (NASDAQ:BWAY) Q1 2024 Earnings Conference Call May 8, 2024 8:30 AM ET Troy Williams – Investor Relations, Life Science Advisors Hadar Levy – Chief Executive Officer Ido Marom – Chief Financial Officer Jeff Cohen – Ladenburg Steve Lichtman – Oppenheimer Ram Selvaraju – H.C. Wainwright Good morning, everyone. My name is Julie, and I will be your conference operator today. At this time, I would like to welcome everyone to BrainsWayÂ's First Quarter 2024 Financial Results Conference Call. All lin ...

Generated Significant 37% Year-over-Year Revenue Growth in Q1 2024 Recorded Positive Quarterly Net Income for Second Consecutive Quarter, and Positive Adjusted EBITDA and Cash Flow from Operations for Third Consecutive Quarter Conference Call to be Held Today at 8:30 AM ET BURLINGTON, Mass. and JERUSALEM, May 08, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a world leader in advanced and non-invasive treatment for brain disorders, today reported first quarter ...

JERUSALEM and BURLINGTON, Mass., April 04, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, announced results published in a review article exploring the potential efficacy of Deep Transcranial Magnetic Stimulation (Deep TMS™) as a novel therapeutic approach for Parkinson's Disease (PD). The paper was published in Frontiers of Human Neuroscience, a leading peer-review ...

D. Risk Factors · Clinical trials involve a lengthy and expensive process with an uncertain outcome, which may delay or cause us to abandon the development of Deep TMS for additional indications. · Our collaboration arrangements may not be successful, which could adversely affect our ability to develop and commercialize our products. Government Regulatory Risks · Our products and operations are subject to extensive government regulation and oversight both in the United States and abroad, and our failure to ...

Brainsway Ltd. Sponsored ADR (BWAY) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the syste ...

BURLINGTON, Mass. and JERUSALEM, March 18, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, announced today that its significant existing partner, Katie's Way Plus, which provides comprehensive mental health services tailored to the unique needs of active duty military members, veterans, and their families, has ordered an additional 18 Deep Transcranial Magnetic Stimu ...

Generally speaking, you want to minimize your exposure to cheap stocks under $10. Yes, smaller companies have the potential to rise dramatically higher than their larger counterparts. In part, that’s because they’re unpredictable – and this ambiguity cuts both ways.Sure, cheap stocks under $10 have the benefit of the law of small numbers working in their favor during upswings. Basically, it doesn’t take as much energy to push a pebble up the mountain. However, if you climb too high up that mountain and you ...

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, March 11th:BrainsWay Ltd. (BWAY) : This company that manufactures non-invasive neurostimulation treatments for mental health disorders has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 13.3% over the last 60 days.BrainsWay’s shares gained 57.1% over the last six months compared with the S&P 500’s advance of 13.9%. The company possesses a Momentum Scor ...

Company Participants Jeffrey Cohen - Ladenburg Thalmann Welcome to BrainsWay's fourth quarter and full year 2023 earnings conference call. With us today are BrainsWay's Chief Executive Officer, Hadar Levy; and Chief Financial Officer, Ido Marom. The format for today's call will be a discussion of recent trends and business updates from Hadar followed by a detailed discussion of the financials. Then we will open up the call for your questions. Earlier today, BrainsWay released financial results for the three ...